HOME | ISSUE ONE (Jan - Mar) 2017 HTML

HUMANITIES SCIENCE POLITICS

Science, People & Politics ISSN 1751-598X

NEWS | 7

than to words developed for litigation. By "The Time" the judges mean when UC inventors
published their research in Science [Jinek et al] in August 2012(1).

The judges write,

"... we are still persuaded by Dr Carroll's statement made contemporaneously to Jinek 2012
'There is no guarantee that cas9 will work effectively on a chromatin target or that the required
DNA-RNA hybrid can be stabilized in that context... Only attempts to apply the system in
eukaryotes will address these concerns."

Though cited by the judges in support of their finding for the Broad, Dr Carroll was UC's expert
witness. The judges write also that a scientist's enthusiasm for their own work is not a
convincing argument that CRISPR-cas9 had an obvious chance of success in eukaryotes. Nor
did they accept that because the application of CRISPR-cas9 had worked in eukaryotes that
that meant it was obvious it would work.

_________________
*CRISPR-cas is an acronym for Clustered Regularly Interspersed Short Palindromic Repeats
associated with Cas. Cas is a protein.

_________________
(1). Jinek et al (2012). "A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive
Bacterial Immunity", Science 337 pp 816-821 DOI: 10.1126/science.1225829

Helen Gavaghan edited the patents page in the technology section of New Scientist for three
years as one of her duties during the 7 years she was on staff at the magazine.

7

Issue 1 (Jan-Mar), 2017............................................Science, People & Politics ISSN 1751-598X print and online


|
|*
*

CONTENTS

P3

P4

P5

P6

P7

P8

P10

P12

P13

P14

P15

P16

Published Friday 24th February, 2017,
nominally.
Completed 9th April, 2017.

P17

P18

P19

P20

P21

P22

P23

P24

P25

P26

P27

P28

P29

P30

P31

HTML/CSS by Helen Gavaghan©